Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: AMPLYX PHARMACEUTICALS, INC.
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Department of the Army
Period of performance: 2018-03-06 to 2021-12-05
Current total value of award: $2734526
Description: ULO DE-OBLIGATION PER SECTION 711 OF THE 2019 NDAA, USAMRAA TRANSFERRED TO DHA 10/1/2022.